-
ImmunoCellular Therapeutics (IMUC) Prices 26.65M Common, 18.66M Warrants Offering
-
Roth Remains Positive on ImmunoCellular (IMUC) Following ICT-107 Phase 2 Presentation at SNO
-
Roth Comments on ImmunoCellular's (IMUC) Licensing Agreement with Caltech; Affirms at 'Buy'
-
Roth Comments on ImmunoCellular (IMUC) Following ICT-107 Updates; Affirms 'Buy' Rating
-
UPDATE: Roth Capital Upgrades ImmunoCellular Therapeutics (IMUC) to Buy
-
Roth Keeps ImmunoCellular (IMUC) at Neutral; Sidelined Until ICT-107 Picture Clears
-
Roth Capital Keeps ImmunoCellular (IMUC) at Neutral; Sidelined Until More ICT-107 Answers Appear
-
Roth Capital Downgrades ImmunoCellular Therapeutics (IMUC) to Neutral
-
Notable 52-Week Highs and Lows of the Day 11/26: (IMUC) (YPF) (TIF) High; (NUAN) (EBAY) Low
-
Cedars-Sinai Brain Cancer Study Shows 50% vs 10% of Patients Alive After Five Years (IMUC)
-
Unusual 11 Mid-Day Movers 11/25: (CAMT) (PBMD) (ARIA) Higher; (ICLD) (UNXL) (RCON) Lower
-
ImmunoCellular (IMUC) Continues Higher After Added to Focus List at Roth
-
Roth Capital Starts ImmunoCellular Therapeutics (IMUC) at Buy
-
Notable Analyst Rating Changes 09/06: (AKS) (ATVI) (GOLD) Upgraded; (NOK) (CLF) (OCZ) Downgraded

